|Bid||0.00 x 1100|
|Ask||12.24 x 800|
|Day's Range||11.86 - 12.46|
|52 Week Range||7.26 - 17.48|
|Beta (5Y Monthly)||1.32|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 27, 2023 - Mar 03, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.80|
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer, Chief Executive Officer, and Kelly MacDonald, Chief Financial Officer, will participate in two upcoming investor conferences:
Dynavax Technologies ( NASDAQ:DVAX ) Third Quarter 2022 Results Key Financial Results Revenue: US$167.7m (up 55% from...
Dynavax Technologies (DVAX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.